0.7901
price down icon6.97%   -0.0592
after-market アフターアワーズ: .82 0.0299 +3.78%
loading
前日終値:
$0.8493
開ける:
$0.8201
24時間の取引高:
1.95M
Relative Volume:
0.88
時価総額:
$91.02M
収益:
$13.45M
当期純損益:
$-178.23M
株価収益率:
-0.4788
EPS:
-1.65
ネットキャッシュフロー:
$-132.53M
1週間 パフォーマンス:
-16.02%
1か月 パフォーマンス:
-29.46%
6か月 パフォーマンス:
-77.43%
1年 パフォーマンス:
-89.24%
1日の値動き範囲:
Value
$0.76
$0.825
1週間の範囲:
Value
$0.76
$0.9496
52週間の値動き範囲:
Value
$0.76
$7.345

Fate Therapeutics Inc Stock (FATE) Company Profile

Name
名前
Fate Therapeutics Inc
Name
セクター
Healthcare (1164)
Name
電話
858.875.1803
Name
住所
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Name
職員
181
Name
Twitter
@fatethx
Name
次回の収益日
2025-03-05
Name
最新のSEC提出書
Name
FATE's Discussions on Twitter

FATE を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
FATE
Fate Therapeutics Inc
0.7901 91.02M 13.45M -178.23M -132.53M -1.65
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-11-18 アップグレード BofA Securities Underperform → Neutral
2024-06-17 アップグレード Piper Sandler Neutral → Overweight
2023-03-27 再開されました Wells Fargo Equal Weight
2023-01-24 ダウングレード H.C. Wainwright Buy → Neutral
2023-01-06 ダウングレード BMO Capital Markets Outperform → Market Perform
2023-01-06 ダウングレード BofA Securities Buy → Underperform
2023-01-06 ダウングレード Cowen Outperform → Market Perform
2023-01-06 ダウングレード Piper Sandler Overweight → Neutral
2023-01-06 ダウングレード Stifel Buy → Hold
2023-01-06 ダウングレード Truist Buy → Hold
2023-01-06 ダウングレード Wedbush Outperform → Neutral
2023-01-03 ダウングレード Guggenheim Buy → Neutral
2022-12-22 ダウングレード Oppenheimer Outperform → Perform
2022-12-15 開始されました Goldman Sell
2022-11-04 再開されました Cantor Fitzgerald Overweight
2022-10-10 開始されました Canaccord Genuity Buy
2022-08-18 再開されました Wells Fargo Overweight
2022-07-28 開始されました Needham Hold
2022-07-11 アップグレード BMO Capital Markets Market Perform → Outperform
2022-06-03 開始されました Robert W. Baird Neutral
2022-02-11 再開されました BMO Capital Markets Market Perform
2021-12-15 アップグレード Wedbush Neutral → Outperform
2021-12-07 開始されました Cowen Outperform
2021-11-09 アップグレード Citigroup Neutral → Buy
2021-08-26 開始されました Morgan Stanley Equal-Weight
2021-06-07 アップグレード H.C. Wainwright Neutral → Buy
2021-05-07 アップグレード Wedbush Neutral → Outperform
2021-04-26 再開されました Jefferies Buy
2021-02-26 開始されました BofA Securities Buy
2021-02-26 ダウングレード Wedbush Outperform → Neutral
2021-02-11 ダウングレード Citigroup Buy → Neutral
2021-01-27 再開されました H.C. Wainwright Neutral
2020-05-13 開始されました H.C. Wainwright Buy
2020-03-04 開始されました Barclays Overweight
2020-01-09 ダウングレード BMO Capital Markets Outperform → Market Perform
2019-12-30 繰り返されました Mizuho Buy
2019-12-09 アップグレード Wells Fargo Market Perform → Outperform
2019-11-12 開始されました SunTrust Buy
2019-11-06 ダウングレード Wells Fargo Outperform → Market Perform
2019-10-01 開始されました Stifel Buy
2019-08-09 開始されました BTIG Research Buy
2019-07-22 開始されました Cantor Fitzgerald Overweight
2019-07-12 開始されました Oppenheimer Outperform
2019-06-13 開始されました Mizuho Buy
2019-06-07 開始されました ROTH Capital Neutral
2019-05-31 開始されました Guggenheim Buy
2019-05-24 再開されました Citigroup Buy
2019-03-28 開始されました SVB Leerink Outperform
2019-01-03 ダウングレード Stephens Overweight → Equal-Weight
2018-11-05 開始されました Jefferies Buy
2018-08-01 開始されました Citigroup Buy
2018-03-06 ダウングレード H.C. Wainwright Buy → Neutral
すべてを表示

Fate Therapeutics Inc (FATE) 最新ニュース

pulisher
Mar 21, 2025

Weekly Research Analysts’ Ratings Updates for Fate Therapeutics (FATE) - Defense World

Mar 21, 2025
pulisher
Mar 21, 2025

Equities Analysts Issue Forecasts for FATE FY2025 Earnings - Defense World

Mar 21, 2025
pulisher
Mar 13, 2025

Fate Therapeutics Inc. Faces Global Expansion Challenges Amid Political and Economic Uncertainties - MSN

Mar 13, 2025
pulisher
Mar 13, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Recommendation of “Hold” from Analysts - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

Fate Therapeutics’ SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 12, 2025

Fate Therapeutics’ SWOT analysis: promising pipeline drives stock outlook - Investing.com

Mar 12, 2025
pulisher
Mar 12, 2025

Fate Therapeutics at Leerink Conference: Strategic Shift to FT-819 By Investing.com - Investing.com UK

Mar 12, 2025
pulisher
Mar 11, 2025

Fate Therapeutics at Barclays Conference: Strategic Shift to Autoimmune Focus - Investing.com UK

Mar 11, 2025
pulisher
Mar 11, 2025

Fate Therapeutics (NASDAQ:FATE) Rating Lowered to “Sell” at StockNews.com - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

Fate Therapeutics price target lowered to $2.50 from $3 at BofA - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Q1 EPS Estimates for Fate Therapeutics Boosted by Wedbush - Defense World

Mar 10, 2025
pulisher
Mar 08, 2025

Fate Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 08, 2025
pulisher
Mar 08, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Just Reported, And Analysts Assigned A US$6.00 Price Target - Yahoo Finance

Mar 08, 2025
pulisher
Mar 08, 2025

Stifel Nicolaus Lowers Fate Therapeutics (NASDAQ:FATE) Price Target to $3.00 - Defense World

Mar 08, 2025
pulisher
Mar 08, 2025

Wedbush Reaffirms Neutral Rating for Fate Therapeutics (NASDAQ:FATE) - Defense World

Mar 08, 2025
pulisher
Mar 08, 2025

Needham & Company LLC Reiterates Hold Rating for Fate Therapeutics (NASDAQ:FATE) - Defense World

Mar 08, 2025
pulisher
Mar 08, 2025

Wells Fargo & Company Has Lowered Expectations for Fate Therapeutics (NASDAQ:FATE) Stock Price - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

Is Fate Therapeutics Inc (NASDAQ: FATE) A Good Investment For New Investors Now? - Stocks Register

Mar 07, 2025
pulisher
Mar 07, 2025

Optimistic Outlook for Fate Therapeutics’ FT819 in Cell-Therapy Space Amid Promising Phase 1 Results - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

Cautious Outlook on Fate Therapeutics Amid FT819 Program Developments and Financial Uncertainties - TipRanks

Mar 07, 2025
pulisher
Mar 06, 2025

Jefferies cuts Fate Therapeutics target to $8, keeps Buy rating By Investing.com - Investing.com Canada

Mar 06, 2025
pulisher
Mar 06, 2025

Stifel cuts Fate Therapeutics stock target to $3, maintains hold By Investing.com - Investing.com Canada

Mar 06, 2025
pulisher
Mar 06, 2025

Cautious Optimism: Hold Rating for Fate Therapeutics Amid Early-Stage Progress and Market Uncertainties - TipRanks

Mar 06, 2025
pulisher
Mar 06, 2025

FATE Q4 Earnings Beat, Autoimmunity, Oncology Programs in Focus - Nasdaq

Mar 06, 2025
pulisher
Mar 06, 2025

Jefferies cuts Fate Therapeutics target to $8, keeps Buy rating - Investing.com India

Mar 06, 2025
pulisher
Mar 06, 2025

Y Intercept Hong Kong Ltd Invests $58,000 in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Mar 06, 2025
pulisher
Mar 06, 2025

Fate Therapeutics: Q4 Earnings Snapshot - mySA

Mar 06, 2025
pulisher
Mar 05, 2025

Fate Therapeutics Advances CAR T-cell Programs Amid Financial Losses - TipRanks

Mar 05, 2025
pulisher
Mar 05, 2025

Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates - MSN

Mar 05, 2025
pulisher
Mar 05, 2025

Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates - Marketscreener.com

Mar 05, 2025
pulisher
Mar 05, 2025

Fate Therapeutics shares rise as Q4 revenue tops estimates By Investing.com - Investing.com South Africa

Mar 05, 2025
pulisher
Mar 05, 2025

Fate Therapeutics shares rise as Q4 revenue tops estimates - Investing.com

Mar 05, 2025
pulisher
Mar 05, 2025

Fate Therapeutics earnings matched, revenue topped estimates By Investing.com - Investing.com UK

Mar 05, 2025
pulisher
Mar 05, 2025

Fate Therapeutics, Inc Q4 Loss Misses Estimates - Nasdaq

Mar 05, 2025
pulisher
Mar 05, 2025

Fate Therapeutics: Q4 Earnings Snapshot -March 05, 2025 at 04:13 pm EST - Marketscreener.com

Mar 05, 2025
pulisher
Mar 05, 2025

FATE THERAPEUTICS INC SEC 10-K Report - TradingView

Mar 05, 2025
pulisher
Mar 05, 2025

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Mar 05, 2025
pulisher
Mar 04, 2025

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Mar 04, 2025
pulisher
Mar 04, 2025

Fate Therapeutics (NASDAQ:FATE) Upgraded by StockNews.com to Hold Rating - Defense World

Mar 04, 2025
pulisher
Feb 28, 2025

NK Cell Therapy Market on Track for Exponential Growth Amid Rising Pipeline Developments | DelveInsight - GlobeNewswire Inc.

Feb 28, 2025
pulisher
Feb 28, 2025

FATE stock touches 52-week low at $1.03 amid sharp annual decline - Investing.com

Feb 28, 2025
pulisher
Feb 25, 2025

Fate Therapeutics (FATE) Expected to Announce Earnings on Monday - MarketBeat

Feb 25, 2025
pulisher
Feb 22, 2025

Fate Therapeutics (FATE) Projected to Post Earnings on Monday - Defense World

Feb 22, 2025
pulisher
Feb 20, 2025

iTeos Therapeutics (NASDAQ:ITOS) & Fate Therapeutics (NASDAQ:FATE) Head-To-Head Analysis - Defense World

Feb 20, 2025
pulisher
Feb 20, 2025

Fate Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire

Feb 20, 2025
pulisher
Feb 19, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives $6.75 Average PT from Analysts - Armenian Reporter

Feb 19, 2025
pulisher
Feb 18, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Brokerages - MarketBeat

Feb 18, 2025
pulisher
Feb 18, 2025

Q1 Earnings Estimate for FATE Issued By Leerink Partnrs - MarketBeat

Feb 18, 2025
pulisher
Feb 17, 2025

Will Fate Therapeutics (FATE) Report Negative Q4 Earnings? What You Should Know - Yahoo Finance

Feb 17, 2025
pulisher
Feb 17, 2025

Fate Therapeutics (FATE) Projected to Post Quarterly Earnings on Monday - MarketBeat

Feb 17, 2025
pulisher
Feb 17, 2025

FY2024 Earnings Forecast for FATE Issued By Leerink Partnrs - Defense World

Feb 17, 2025

Fate Therapeutics Inc (FATE) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
大文字化:     |  ボリューム (24 時間):